Physician profile
Katherine E Enos
NPI 1528451002
$3,052.42
in general payments reported to CMS, 2019-2025
30 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.14 · 2021: $406 · 2022: $264 · 2023: $650 · 2024: $472 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.84 | 2021-2025 | |
| Novo Nordisk INC | $530.72 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Astellas Pharma US INC | $266.83 | 2022-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $192.16 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $172.24 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $170.06 | 2021-2023 | Spravato |
| Pfizer INC. | $153.97 | 2025 | |
| Glaxosmithkline, LLC. | $136.00 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.86 | 2025 | Caplyta |
| Amgen INC. | $109.43 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Esperion Therapeutics, INC. | $88.13 | 2022 | |
| Lilly USA, LLC | $66.53 | 2023-2025 | Zepbound, Mounjaro |
| Inari Medical, INC. | $49.50 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Exact Sciences Corporation | $47.36 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.29 | 2025 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.14 | 2023 | |
| Medtronic, INC. | $36.65 | 2023-2024 | Intellis Adaptivestim, Venaseal |
| Dynavax Technologies Corporation | $27.90 | 2023-2025 | Heplisav-B |
| Eisai INC. | $24.53 | 2025 | |
| Edwards Lifesciences Corporation | $18.46 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Axsome Therapeutics, INC. | $18.09 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $17.52 | 2025 | |
| Antares Pharma, INC. | $17.33 | 2025 | Xyosted |
| Ascensia Diabetes Care US INC. | $17.10 | 2023 | |
| Inspire Medical Systems, INC. | $16.70 | 2025 | Inspire |
| Shield Therapeutics INC | $15.88 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.08 | 2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.62 | 2025 | Jardiance |
| Halozyme INC | $14.09 | 2023 | |
| Gt Medical Technologies, INC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Enos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.